resulting from infection with HIV or from aggressive medical practices. These patients are especially susceptible to infections by opportunistic fungi leading to mycoses1). In the course of our antifungal screening program, we have devised an efficient screening method for selective toxicity for fungi. We have taken advantage of recent advances in genomics research and technical advances in highthroughput screening (HTS). This paper describes a screening strategy to detect compounds that inhibit any of the steps in the biosynthetic pathway of fungi. This screening method is rapid, robust, sensitive, and suitable for HTS.
We sought homologous proteins between fungi and mammals, which were essential in fungi. We prepared three types of strains for this screening. One expressed DM of Candida albicans (S1) and others expressed that each of human (S2) and rat (S3). If there are compounds that have specific inhibitory activity for the fungal enzyme, S1 will not survive in the presence of these compounds but S2 and S3 will survive. So we can easily screen specific activity of compounds by monitoring difference of growth among S1, S2 and S3.
Establishment of Yeast Strains, S1, S2, and S34) Yeast cultures and manipulations were performed by standard methods5). Yeast S1 strain was constructed as described below. Candida albicans DM gene6) was amplified by PCR using Candida albicans genomic DNA as a template. The PCR product was digested by BamHI and SmaI, and this fragments were subcloned into BamHISmaI sites of pYACT3. This plasmid, expressing Candida albicans DM in yeast, was used to transform Saccharomyces cerevisiae YPH500 (Stratagene). This transformant was subject to disruption of Saccharomyces cerevisiae DM gene (ERG11). The disruption was generated by a one-step gene disruption method involving
Human DM cDNA7) and rat DM cDNA8) were cloned by PCR, using QUICK-Clone cDNA Human Placenta (Clontech) and QUICK-Clone cDNA Rat Liver (Clontech), respectively, as a template. Yeast S2 and S3 strains were constructed by the same method as S1. In the first step, inhibitory activity for the S1 strain was screened.
If growth inhibitory activity for S1 was higher than 50%, the sample was selected as a first hit. Then activities of hit samples were compared at several concentrations for S1, S2, and S3. If the IC50 for S1 was 10 times lower than those for S2 and S3, the sample was designated as a true hit that has selective inhibitory activity against DM of Candida.
Confirmation of Screening Strategy
To confirm the screening strategy, FCZ, ICZ, and MCZ were tested in this assay. Inhibitory activities of these compounds are shown in Fig. 1 . They inhibit the growth of S1 selectively.
Screening of Microbial Fermentation Broths and
Chemical Library Samples we have established this screening for 36,000 samples of microbial culture broths and 30,000 samples from a chemical library. There were no samples that showed selective activity for S1 in the microbial culture broths. Only one compound, 5-Chloro-2-phenyl-1H-benzoimidazole (CPBI), from the chemical library showed selective activity. The structure of CPBI is shown in Fig. 2 and the inhibitory activities for S1, S2, and S3 are shown in Table 1 . The inhibitory concentration for S1 was 10 times lower than for S2 and S3. The MICs of CPBI, FCZ, and MCZ are shown in Table 2 . CPBI has antifungal activity but it also has cell toxicity (data not shown). Antifungal activities have been reported for benzoimidazole 
